Emblok, Inc. is a privately held Tampa, Florida medical device company developing the Emblok Embolic Protection System, a 360-degree whole-body embolic protection device used during transcatheter aortic valve replacement (TAVR). The device is delivered through femoral access, deployed across the aortic arch near the brachiocephalic artery, and captures calcium and tissue debris dislodged during valve replacement before it can reach the brain, kidneys, or visceral arteries. The company was formerly known as Innovative Cardiovascular Solutions. The system is investigational and its clinical use is limited to an FDA-approved study; a US multicenter randomized trial enrolling up to 532 TAVR patients is underway, having passed 50 patients enrolled in October 2024.